Clinical Trials Sponsored by Kowa Company, Ltd

Total 437 results

Kowa Company, Ltd.

Recruiting

A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

Hypercholesterolemia

Japan
Kowa Company, Ltd.

Completed

A Phase III Long Term Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Kowa Company, Ltd.

Completed

K-924 Phase III Long Term Study

Hypercholesterolemia

Japan
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Kowa Company, Ltd.

Completed

A Clinical Pharmacology Study of K-877 Controlled Release Tablet

Dyslipidemias

Japan
Kowa Company, Ltd.

Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

Hyperlipidemia

China
Kowa Company, Ltd.

Completed

K-924 Phase III Confirmatory Study

Hypercholesterolemia

Japan
Kowa Company, Ltd.

Active, not recruiting

A Phase III Confirmatory Study of K-237

Covid19

Japan, Thailand
Kowa Company, Ltd.

Completed

A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

Japan
Kowa Company, Ltd.

Completed

Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC

Hepatic Neoplasm Malignant Recurrent

Japan
Kowa Company, Ltd.

Completed

A Study to Evaluate the Safety of K-755 in Healthy Volunteers

Healthy

Australia
Sanofi
Kowa Company, Ltd.

Completed

TOFO Insulin Combination Trial

Type 2 Diabetes Mellitus

Japan
Kowa Company, Ltd.
Sanofi

Completed

Tofogliflozin GLP-1 Analogue Combination Trial

Type 2 Diabetes Mellitus

Japan
Kanazawa University
Kowa Company, Ltd.

Completed

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Non-alcoholic Fatty Liver Disease

Japan
Osaka University
Kowa Company, Ltd.

Terminated

The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease (PIT-ROAD)

Alzheimer Disease | Hypercholesterolemia

Japan
Shinshu University
Kowa Company, Ltd.

Recruiting

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) (TRUTH-DKD)

T2DM (Type 2 Diabetes Mellitus) | Metformin | SGLT2-Inhibitors

Japan
Chrysantis, Inc.
Kowa Company, Ltd.; IMAGE TECHNOLOGIES INC.

Completed

The Zeaxanthin and Visual Function Study (ZVF)

Cognition Disorders | Age Related Macular Degeneration

United States
Jaeb Center for Health Research
Kowa Company, Ltd.

Terminated

PROMINENT-Eye Ancillary Study (Protocol AD)

Diabetic Retinopathy | Diabetic Macular Edema

United States, Canada
Kowa Research Institute, Inc.
Eli Lilly and Company; Kowa Pharmaceuticals America, Inc.

Completed

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

Dyslipidemia

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.; Kyowa Kirin Korea Co., Ltd.

Completed

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Secondary Hyperparathyroidism

China, Hong Kong, Korea, Republic of, Taiwan
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Japan, Ireland, United Kingdom, France, Italy
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

Korea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

Netherlands, United States, United Kingdom, France
Kyowa Kirin Co., Ltd.

Completed

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

Diabetic Kidney Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis

Healthy Men and Subjects With Ulcerative Colitis

Japan
Kyowa Kirin Co., Ltd.

Active, not recruiting

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Indolent B-cell Non-Hodgkin's Lymphoma

Japan
Kyowa Kirin Co., Ltd.

Completed

Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Active, not recruiting

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Breast Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

KRN125 for Mobilization of Hematopoietic Stem Cells

Peripheral Blood Stem Cell Transplantation

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of RTA 402 in Obese Adults

Obese Adult Male

Japan
Kyowa Kirin Co., Ltd.

Completed

A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 2 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease

Alzheimer Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Extended Long-Term Safety Study of KW-6500 (6500-005)

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Non-small-cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Kyowa Kirin Co., Ltd.

Terminated

A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes | Chronic Kidney Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

Neutropenia

Japan
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Non-small-cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

MDS

Japan, Korea, Republic of
Kyowa Kirin Co., Ltd.

Completed

A Phase IIa Study of KHK4563 (4563-003)

Uncontrolled and Suspected Eosinophilic Asthma

Korea, Republic of, Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Clinical Study of KHK4827

Moderate to Severe Plaque Psoriasis

Japan

Clinical Trials Sponsored by Kowa Company, Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations